To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

NCT01256736 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Tocilizumab
DRUG: DMARDs

Sponsor

JW Pharmaceutical